Steven Shak Sells 5,000 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 5,000 shares of the firm’s stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $31.26, for a total value of $156,300.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Steven Shak also recently made the following trade(s):

  • On Monday, January 23rd, Steven Shak sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $27.28, for a total value of $136,400.00.

Genomic Health, Inc. (NASDAQ:GHDX) opened at 31.88 on Tuesday. The stock has a 50 day moving average price of $30.27 and a 200 day moving average price of $29.78. Genomic Health, Inc. has a 52-week low of $22.90 and a 52-week high of $33.96. The stock’s market cap is $1.09 billion.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, February 14th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.05. Genomic Health had a negative return on equity of 14.13% and a negative net margin of 5.77%. The business had revenue of $82.70 million for the quarter, compared to the consensus estimate of $84.08 million. During the same quarter in the prior year, the company earned ($0.10) EPS. The business’s revenue was up 10.1% compared to the same quarter last year. Analysts expect that Genomic Health, Inc. will post $0.01 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Mideast Time and is owned by of Mideast Time. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.mideasttime.com/steven-shak-sells-5000-shares-of-genomic-health-inc-ghdx-stock/1590207.html.

Several institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP purchased a new position in Genomic Health during the third quarter worth about $398,237,000. Columbia Wanger Asset Management LLC increased its position in Genomic Health by 172.2% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 1,275,338 shares of the company’s stock worth $37,482,000 after buying an additional 806,782 shares during the last quarter. BlackRock Fund Advisors increased its position in Genomic Health by 5.5% in the third quarter. BlackRock Fund Advisors now owns 914,017 shares of the company’s stock worth $26,433,000 after buying an additional 47,996 shares during the last quarter. Renaissance Technologies LLC increased its position in Genomic Health by 5.3% in the fourth quarter. Renaissance Technologies LLC now owns 576,700 shares of the company’s stock worth $16,949,000 after buying an additional 29,100 shares during the last quarter. Finally, State Street Corp increased its position in Genomic Health by 6.6% in the fourth quarter. State Street Corp now owns 545,119 shares of the company’s stock worth $16,024,000 after buying an additional 33,975 shares during the last quarter. 89.50% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have commented on GHDX shares. Canaccord Genuity reissued a “buy” rating and set a $38.00 price objective on shares of Genomic Health in a research report on Tuesday, January 17th. TheStreet raised Genomic Health from a “d+” rating to a “c-” rating in a research report on Monday, February 27th. Zacks Investment Research lowered Genomic Health from a “buy” rating to a “hold” rating in a research report on Thursday, January 19th. Deutsche Bank AG reissued a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a research report on Wednesday, January 18th. Finally, Cowen and Company lowered Genomic Health from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $35.00 to $34.00 in a research report on Wednesday, January 4th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $31.14.

About Genomic Health

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

5 Day Chart for NASDAQ:GHDX

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.